Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Osanetant may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Osanetant. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Osanetant. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Osanetant. |
| Hydrocodone | Osanetant may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Osanetant. |
| Magnesium sulfate | The therapeutic efficacy of Osanetant can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Osanetant may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Osanetant may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Osanetant. |
| Mirtazapine | Osanetant may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Osanetant. |
| Orphenadrine | Osanetant may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Osanetant may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Osanetant. |
| Pramipexole | Osanetant may increase the sedative activities of Pramipexole. |
| Ropinirole | Osanetant may increase the sedative activities of Ropinirole. |
| Rotigotine | Osanetant may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Osanetant. |
| Sodium oxybate | Osanetant may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Osanetant may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Osanetant. |
| Thalidomide | Osanetant may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Osanetant may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amisulpride | Osanetant may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Osanetant is combined with Methylphenidate. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when Osanetant is combined with Dexmethylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Osanetant. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Osanetant. |
| Sulpiride | Osanetant may increase the antipsychotic activities of Sulpiride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Osanetant. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of Osanetant. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of Osanetant. |
| Mequitazine | Osanetant may increase the arrhythmogenic activities of Mequitazine. |
| Tetrabenazine | The risk or severity of adverse effects can be increased when Osanetant is combined with Tetrabenazine. |
| Deutetrabenazine | The risk or severity of adverse effects can be increased when Osanetant is combined with Deutetrabenazine. |
| Ethanol | Osanetant may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Osanetant may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Osanetant. |
| Zimelidine | The risk or severity of adverse effects can be increased when Osanetant is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Osanetant is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Osanetant is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Osanetant is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Osanetant is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Osanetant is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Osanetant is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Osanetant is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Osanetant is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Osanetant is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Osanetant is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Osanetant is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Osanetant is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Osanetant is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Osanetant. |
| Indalpine | The risk or severity of adverse effects can be increased when Osanetant is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Osanetant is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Osanetant is combined with Alaproclate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Osanetant. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Osanetant. |
| Zopiclone | The risk or severity of adverse effects can be increased when Osanetant is combined with Zopiclone. |
| Eletriptan | The risk or severity of adverse effects can be increased when Eletriptan is combined with Osanetant. |
| Cabergoline | The risk or severity of adverse effects can be increased when Cabergoline is combined with Osanetant. |
| Zolmitriptan | The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Osanetant. |
| Dihydroergotamine | The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Osanetant. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Osanetant. |
| Dextromethorphan | The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Osanetant. |
| Mazindol | The risk or severity of adverse effects can be increased when Mazindol is combined with Osanetant. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Osanetant. |
| Sumatriptan | The risk or severity of adverse effects can be increased when Sumatriptan is combined with Osanetant. |
| Ergotamine | The risk or severity of adverse effects can be increased when Ergotamine is combined with Osanetant. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Osanetant. |
| Almotriptan | The risk or severity of adverse effects can be increased when Almotriptan is combined with Osanetant. |
| Naratriptan | The risk or severity of adverse effects can be increased when Naratriptan is combined with Osanetant. |
| Rizatriptan | The risk or severity of adverse effects can be increased when Rizatriptan is combined with Osanetant. |
| Frovatriptan | The risk or severity of adverse effects can be increased when Frovatriptan is combined with Osanetant. |
| Ergoloid mesylate | The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Osanetant. |
| Chlorpheniramine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Osanetant. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Osanetant. |
| Bromocriptine | The risk or severity of adverse effects can be increased when Bromocriptine is combined with Osanetant. |
| Ergometrine | The risk or severity of adverse effects can be increased when Ergometrine is combined with Osanetant. |
| Rasagiline | The risk or severity of adverse effects can be increased when Rasagiline is combined with Osanetant. |
| Lorcaserin | The risk or severity of adverse effects can be increased when Lorcaserin is combined with Osanetant. |
| Etoperidone | The risk or severity of adverse effects can be increased when Etoperidone is combined with Osanetant. |
| Lorpiprazole | The risk or severity of adverse effects can be increased when Lorpiprazole is combined with Osanetant. |
| Amphetamine | Osanetant may decrease the stimulatory activities of Amphetamine. |
| Phentermine | Osanetant may decrease the stimulatory activities of Phentermine. |
| Pseudoephedrine | Osanetant may decrease the stimulatory activities of Pseudoephedrine. |
| Benzphetamine | Osanetant may decrease the stimulatory activities of Benzphetamine. |
| Diethylpropion | Osanetant may decrease the stimulatory activities of Diethylpropion. |
| Lisdexamfetamine | Osanetant may decrease the stimulatory activities of Lisdexamfetamine. |
| Mephentermine | Osanetant may decrease the stimulatory activities of Mephentermine. |
| MMDA | Osanetant may decrease the stimulatory activities of MMDA. |
| 2,5-Dimethoxy-4-ethylamphetamine | Osanetant may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. |
| Chlorphentermine | Osanetant may decrease the stimulatory activities of Chlorphentermine. |
| Methylenedioxyethamphetamine | Osanetant may decrease the stimulatory activities of Methylenedioxyethamphetamine. |
| Dextroamphetamine | Osanetant may decrease the stimulatory activities of Dextroamphetamine. |
| Metamfetamine | Osanetant may decrease the stimulatory activities of Metamfetamine. |
| Iofetamine I-123 | Osanetant may decrease the stimulatory activities of Iofetamine I-123. |
| Ritobegron | Osanetant may decrease the stimulatory activities of Ritobegron. |
| Mephedrone | Osanetant may decrease the stimulatory activities of Mephedrone. |